130 related articles for article (PubMed ID: 36055919)
1. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.
Rizzolo A; Ah-Lan KC; Nu TNT; Alcindor T
Clin Colorectal Cancer; 2022 Dec; 21(4):371-374. PubMed ID: 36055919
[No Abstract] [Full Text] [Related]
2. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
[No Abstract] [Full Text] [Related]
3. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
[No Abstract] [Full Text] [Related]
4. Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.
Cancer Discov; 2017 Aug; 7(8):OF7. PubMed ID: 28592400
[TBL] [Abstract][Full Text] [Related]
5. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
6. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
Maller B; Peguero E; Tanvetyanon T
J Immunother; 2018; 41(9):411-412. PubMed ID: 29742520
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma clinical trial combines immunotherapy drugs.
Chatwal MS; Tanvetyanon T
Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for pediatric malignant peritoneal mesothelioma.
Yaman Ortaköylü M; İncesoy Özdemir S; Dinçaslan H; Taçyıldız N; Ünal AE; Soydal Ç; Fitöz ÖS; Ünal E
Pediatr Blood Cancer; 2023 Feb; 70(2):e29892. PubMed ID: 35851543
[No Abstract] [Full Text] [Related]
11. A case report of peritoneal malignant mesothelioma presenting as primary ovarian mass.
Kapoor R; Kuttikat PG; Vaiphei K; Rai B; Patel FD
J Cancer Res Ther; 2015; 11(3):654. PubMed ID: 26458642
[TBL] [Abstract][Full Text] [Related]
12. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
13. Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Tang LK; Li ZK; Xiang YL; Ma DY; Du GB
Medicine (Baltimore); 2023 Jul; 102(30):e34349. PubMed ID: 37505161
[TBL] [Abstract][Full Text] [Related]
14. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
Yagi Y; Maeda T; Yoshimitsu Y; Sakuma H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
[TBL] [Abstract][Full Text] [Related]
15. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
18. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
